董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Miller | 男 | Director | 81 | 2.92万美元 | 未持股 | 2017-04-24 |
| Michael S. Sitrick | 男 | Director | 69 | 3.21万美元 | 未持股 | 2017-04-24 |
| Michael Blaszyk | 男 | Director | 64 | 3.50万美元 | 未持股 | 2017-04-24 |
| Mark Burnett | 男 | Director | 56 | 210.89万美元 | 未持股 | 2017-04-24 |
| Kirk K. Calhoun | 男 | Director | 73 | 2.92万美元 | 未持股 | 2017-04-24 |
| Patrick Soon Shiong | 男 | Chairman and Chief Executive Officer and Director | 64 | 未披露 | 未持股 | 2017-04-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul A. Holt | 男 | Chief Financial Officer | 50 | 91.50万美元 | 未持股 | 2017-04-24 |
| Patrick Soon Shiong | 男 | Chairman and Chief Executive Officer and Director | 64 | 未披露 | 未持股 | 2017-04-24 |
董事简历
中英对照 | 中文 | 英文- Edward Miller
-
Edward Miller， 是医学博士，担任我们的董事（2016年5月以来）。他曾一直担任Noxilizer, Inc.的董事（2000年以来），以及PNC Mutual Funds的董事（1997年以来）。从2009年到2015年，他担任CareFusion Corporation的董事。他曾担任The Johns Hopkins University School of Medicine的首席执行官兼院长（1997年到2012年）。此前，他曾担任The Johns Hopkins University的医学副校长、Columbia Presbyterian Medical Center的麻醉学系教授和主任、the University of Virginia的教授。他持有Ohio Wesleyan University的学士学位、the University of Rochester School of Medicine and Dentistry的医学博士学位，也是Harvard Medical School的生理学研究员。他是the Institute of Medicine of the National Academy of Sciences的成员，也曾担任the Association of University Anesthesiologists的总裁，是the Royal College of Physicians、the Royal College of Anaesthetists的成员。他还撰写或共同撰写大量的科学论文、摘要和图书章节。
Edward Miller has served on our board of directors since May 2016. Dr. Miller has served as a director of Noxilizer, Inc. since 2000 and as a director of PNC Mutual Funds since 1997. From 2009 to 2015 Dr. Miller served as a director of CareFusion Corporation. From 1997 to 2012 Dr. Miller was the Chief Executive Officer and dean of The Johns Hopkins University School of Medicine. Prior to that, Dr. Miller served as vice president for medicine of The Johns Hopkins University, as a professor and Chairman of the Department of Anesthesiology at Columbia Presbyterian Medical Center, and as a professor at the University of Virginia. Dr. Miller received his A.B. from Ohio Wesleyan University and his M.D. from the University of Rochester School of Medicine and Dentistry, and was a research fellow in physiology at Harvard Medical School. Dr. Miller is a member of the Institute of Medicine of the National Academy of Sciences, has served as president of the Association of University Anesthesiologists, and is a fellow of the Royal College of Physicians and the Royal College of Anaesthetists. - Edward Miller， 是医学博士，担任我们的董事（2016年5月以来）。他曾一直担任Noxilizer, Inc.的董事（2000年以来），以及PNC Mutual Funds的董事（1997年以来）。从2009年到2015年，他担任CareFusion Corporation的董事。他曾担任The Johns Hopkins University School of Medicine的首席执行官兼院长（1997年到2012年）。此前，他曾担任The Johns Hopkins University的医学副校长、Columbia Presbyterian Medical Center的麻醉学系教授和主任、the University of Virginia的教授。他持有Ohio Wesleyan University的学士学位、the University of Rochester School of Medicine and Dentistry的医学博士学位，也是Harvard Medical School的生理学研究员。他是the Institute of Medicine of the National Academy of Sciences的成员，也曾担任the Association of University Anesthesiologists的总裁，是the Royal College of Physicians、the Royal College of Anaesthetists的成员。他还撰写或共同撰写大量的科学论文、摘要和图书章节。
- Edward Miller has served on our board of directors since May 2016. Dr. Miller has served as a director of Noxilizer, Inc. since 2000 and as a director of PNC Mutual Funds since 1997. From 2009 to 2015 Dr. Miller served as a director of CareFusion Corporation. From 1997 to 2012 Dr. Miller was the Chief Executive Officer and dean of The Johns Hopkins University School of Medicine. Prior to that, Dr. Miller served as vice president for medicine of The Johns Hopkins University, as a professor and Chairman of the Department of Anesthesiology at Columbia Presbyterian Medical Center, and as a professor at the University of Virginia. Dr. Miller received his A.B. from Ohio Wesleyan University and his M.D. from the University of Rochester School of Medicine and Dentistry, and was a research fellow in physiology at Harvard Medical School. Dr. Miller is a member of the Institute of Medicine of the National Academy of Sciences, has served as president of the Association of University Anesthesiologists, and is a fellow of the Royal College of Physicians and the Royal College of Anaesthetists.
- Michael S. Sitrick
-
Michael S. Sitrick，自1995年10月起担任董事长。1976年起，Skala先生一直是法律公司Feder Kaszovitz LLP，的合伙人和我们的法律总顾问。
Michael S. Sitrick has been a Director since December 19 2014. Since November 2009 Mr. Sitrick is the chairman and chief executive officer of Sitrick Brinko LLC, a subsidiary of Resources Connection, Inc. NASDAQ: RECN, and the successor to Sitrick And Company, which he founded in 1989 and was its chairman and chief executive officer until he sold it in 2009 to Resources Connection, Inc., a public relations, strategic communications and crisis management company providing advice and counseling to some of the country’s largest corporations, non-profits and governmental agencies, in many areas including mergers and acquisitions, litigation support, corporate positioning and repositioning, developing and implementing strategies to deal with short sellers, executive transitions and government investigations. Prior thereto he was Senior Vice President - Communications for Wickes Companies, Inc. (from 1981to1989), head of Communications and Government Affairs for National Can Corporation (from 1974 to 1981), and Group Supervisor at Selz, Seabolt and Associates before that. Prior thereto Mr. Sitrick was Assistant Director of Public Information in the Richard J. Daley administration in Chicago and worked as a reporter. Mr. Sitrick is a published author, frequent lecturer, former Board member at two public companies (both of which were sold), and current or former Board member of several charitable organizations. He holds a B.S. degree in Business Administration and a major in Journalism from the University of Maryland, College Park. - Michael S. Sitrick，自1995年10月起担任董事长。1976年起，Skala先生一直是法律公司Feder Kaszovitz LLP，的合伙人和我们的法律总顾问。
- Michael S. Sitrick has been a Director since December 19 2014. Since November 2009 Mr. Sitrick is the chairman and chief executive officer of Sitrick Brinko LLC, a subsidiary of Resources Connection, Inc. NASDAQ: RECN, and the successor to Sitrick And Company, which he founded in 1989 and was its chairman and chief executive officer until he sold it in 2009 to Resources Connection, Inc., a public relations, strategic communications and crisis management company providing advice and counseling to some of the country’s largest corporations, non-profits and governmental agencies, in many areas including mergers and acquisitions, litigation support, corporate positioning and repositioning, developing and implementing strategies to deal with short sellers, executive transitions and government investigations. Prior thereto he was Senior Vice President - Communications for Wickes Companies, Inc. (from 1981to1989), head of Communications and Government Affairs for National Can Corporation (from 1974 to 1981), and Group Supervisor at Selz, Seabolt and Associates before that. Prior thereto Mr. Sitrick was Assistant Director of Public Information in the Richard J. Daley administration in Chicago and worked as a reporter. Mr. Sitrick is a published author, frequent lecturer, former Board member at two public companies (both of which were sold), and current or former Board member of several charitable organizations. He holds a B.S. degree in Business Administration and a major in Journalism from the University of Maryland, College Park.
- Michael Blaszyk
-
Michael Blaszyk，2015年7月以来，他曾一直担任我们董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
Michael Blaszyk has served as a member of our board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor’s degree in life sciences from Wayne State University and his master’s degree in health services administration from the University of Colorado. - Michael Blaszyk，2015年7月以来，他曾一直担任我们董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
- Michael Blaszyk has served as a member of our board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor’s degree in life sciences from Wayne State University and his master’s degree in health services administration from the University of Colorado.
- Mark Burnett
-
Mark Burnett， 2009年6月以来，一直是我们董事会的成员，目前是我们的薪酬委员会和审计委员会的成员。Burnett先生是MercBloc公司（MercBloc, LLC）的执行副总裁兼首席执行官，MercBloc公司是2007年他合伙创建的。MercBloc公司是金融服务管理人，已经从70多个高净资产拥有者那里筹集到500多万美元的投资。Burnett先生也是Fuse Capital有限责任公司（Fuse Capital, LLC）的管理人员，Fuse Capital有限责任公司是一家私人证券交易和投资公司。自1996年以来，Burnett先生也一直从事纽约长岛的Nassau县地区（Nassau County region of Long Island, New York。）住宅的建筑。他保持在纽约商品交易所（New York Mercantile Exchange）的席位超过25年，他以燃料油和原油期货交易合同开始了职业生涯。他是纽约商品交易所（NYMEX）的成员，目前，拥有在芝加哥气候期货交易所Chicago Climate Futures Exchange、国际知识产权交易所公司（Intellectual Property Exchange International）的会员资格。1981年，Burnett先生毕业于纽约州立大学石溪分校（State University of New York at Stony Brook）。
Mark Burnett has served as a member of our board of directors since May 2016. Mr. Burnett has been the President of the MGM Television and Digital Group since January 2016 and is an eight-time Emmy Award winner. Mr. Burnett has produced more than 3200 hours of television programming, which regularly airs in more than 70 countries worldwide. The group Mr. Burnett leads currently has numerous TV shows airing or in production, including “The Voice” NBC; “Survivor” (CBS); “Shark Tank” (ABC); “Fargo” (FX); “Vikings” (HISTORY); “Beyond the Tank” (ABC); “Celebrity Apprentice” (NBC); “Teen Wolf” (MTV); “500 Questions” (ABC); “The People’s Choice Awards” (CBS); “Lucha Underground” (El Rey Network); and “America’s Greatest Makers” (INTEL/Turner Awards (CBS)). Mr. Burnett is one of very few producers to have had a renewed series of each of the four major networks and to have multiple series win their time slots on five nights of television in the same week. Prior to joining MGM, Mr. Burnett was a director and Chief Executive Officer of One Three Media from April 2011 until September 2014 and was a director and Chief Executive Officer of UAMG, LLC from September 2014 until January 2016. Mr. Burnett has also served as a director of Lightworkers Media OTT, LLC and its predecessor entities since December 2012. Mr. Burnett is also a director of our affiliate, NantBioScience, Inc. - Mark Burnett， 2009年6月以来，一直是我们董事会的成员，目前是我们的薪酬委员会和审计委员会的成员。Burnett先生是MercBloc公司（MercBloc, LLC）的执行副总裁兼首席执行官，MercBloc公司是2007年他合伙创建的。MercBloc公司是金融服务管理人，已经从70多个高净资产拥有者那里筹集到500多万美元的投资。Burnett先生也是Fuse Capital有限责任公司（Fuse Capital, LLC）的管理人员，Fuse Capital有限责任公司是一家私人证券交易和投资公司。自1996年以来，Burnett先生也一直从事纽约长岛的Nassau县地区（Nassau County region of Long Island, New York。）住宅的建筑。他保持在纽约商品交易所（New York Mercantile Exchange）的席位超过25年，他以燃料油和原油期货交易合同开始了职业生涯。他是纽约商品交易所（NYMEX）的成员，目前，拥有在芝加哥气候期货交易所Chicago Climate Futures Exchange、国际知识产权交易所公司（Intellectual Property Exchange International）的会员资格。1981年，Burnett先生毕业于纽约州立大学石溪分校（State University of New York at Stony Brook）。
- Mark Burnett has served as a member of our board of directors since May 2016. Mr. Burnett has been the President of the MGM Television and Digital Group since January 2016 and is an eight-time Emmy Award winner. Mr. Burnett has produced more than 3200 hours of television programming, which regularly airs in more than 70 countries worldwide. The group Mr. Burnett leads currently has numerous TV shows airing or in production, including “The Voice” NBC; “Survivor” (CBS); “Shark Tank” (ABC); “Fargo” (FX); “Vikings” (HISTORY); “Beyond the Tank” (ABC); “Celebrity Apprentice” (NBC); “Teen Wolf” (MTV); “500 Questions” (ABC); “The People’s Choice Awards” (CBS); “Lucha Underground” (El Rey Network); and “America’s Greatest Makers” (INTEL/Turner Awards (CBS)). Mr. Burnett is one of very few producers to have had a renewed series of each of the four major networks and to have multiple series win their time slots on five nights of television in the same week. Prior to joining MGM, Mr. Burnett was a director and Chief Executive Officer of One Three Media from April 2011 until September 2014 and was a director and Chief Executive Officer of UAMG, LLC from September 2014 until January 2016. Mr. Burnett has also served as a director of Lightworkers Media OTT, LLC and its predecessor entities since December 2012. Mr. Burnett is also a director of our affiliate, NantBioScience, Inc.
- Kirk K. Calhoun
-
Kirk K. Calhoun从2008年5月开始担任董事，从2011年12月开始担任首席董事的职位。Calhoun先生在1965年加入Ernst & Young，一家上市会计事务所，担任事务所合伙人从1975年到他在2002年退休为止。Calhoun先生是非执业注册会计师，拥有审计和会计的背景。他服务于5家上市医药行业的公司的董事会和审计委员会的成员，直到他们分别出售为止，包括Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. 和Adams Respiratory Therapeutics, Inc.Calhoun先生目前也担任三家私人企业的董事，包括NeuroSigma，是一家治疗严重的神经和神经精神疾病如癫痫症和抑郁症的产品的开发公司。Calhoun先生拥有the University of Southern California。的会计学士学位。
Kirk K. Calhoun has served as a member of our board of directors since May 2016. Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965 and served as a partner of the firm from 1975 until his retirement in 2002. Mr. Calhoun is a Certified Public Accountant non-practicing with a background in auditing and accounting. He has previously served on the boards and audit committees of six public companies in the pharmaceutical and medical diagnostic industries up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc., Adams Respiratory Therapeutics, Inc. and Response Genetics, Inc. Mr. Calhoun currently serves on the boards of Ryerson Holding Corporation (NYSE: RYI), a metals processor and distributor, and Great Basin Corporation (OTCQB: GBSN), a molecular diagnostic testing company using chip-based technologies, plus three private companies, including NeuroSigma, Inc., a developer of products treating major neurological and neuropsychiatric disorders, and PLx Pharma, Inc. (NASDAQ: PLXP), a late stage startup specialty pharmaceutical company focused on commercializing aspirin products. Mr. Calhoun received a BS in accounting from the University of Southern California. - Kirk K. Calhoun从2008年5月开始担任董事，从2011年12月开始担任首席董事的职位。Calhoun先生在1965年加入Ernst & Young，一家上市会计事务所，担任事务所合伙人从1975年到他在2002年退休为止。Calhoun先生是非执业注册会计师，拥有审计和会计的背景。他服务于5家上市医药行业的公司的董事会和审计委员会的成员，直到他们分别出售为止，包括Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. 和Adams Respiratory Therapeutics, Inc.Calhoun先生目前也担任三家私人企业的董事，包括NeuroSigma，是一家治疗严重的神经和神经精神疾病如癫痫症和抑郁症的产品的开发公司。Calhoun先生拥有the University of Southern California。的会计学士学位。
- Kirk K. Calhoun has served as a member of our board of directors since May 2016. Mr. Calhoun joined Ernst & Young LLP, a public accounting firm, in 1965 and served as a partner of the firm from 1975 until his retirement in 2002. Mr. Calhoun is a Certified Public Accountant non-practicing with a background in auditing and accounting. He has previously served on the boards and audit committees of six public companies in the pharmaceutical and medical diagnostic industries up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc., Adams Respiratory Therapeutics, Inc. and Response Genetics, Inc. Mr. Calhoun currently serves on the boards of Ryerson Holding Corporation (NYSE: RYI), a metals processor and distributor, and Great Basin Corporation (OTCQB: GBSN), a molecular diagnostic testing company using chip-based technologies, plus three private companies, including NeuroSigma, Inc., a developer of products treating major neurological and neuropsychiatric disorders, and PLx Pharma, Inc. (NASDAQ: PLXP), a late stage startup specialty pharmaceutical company focused on commercializing aspirin products. Mr. Calhoun received a BS in accounting from the University of Southern California.
- Patrick Soon Shiong
-
Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. - Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
- Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.
高管简历
中英对照 | 中文 | 英文- Paul A. Holt
Paul A. Holt， 他于2000年11月被任命为我们的首席财务官。他曾担任我们的总会计师（从2000年1月到2000年5月），并于2000年5月被任命为临时首席财务官。加入我们之前，他曾担任Sierra Alloys公司（钛金属制造公司）的总会计师（从1999年8月到1999年12月）。从1997年5月到1997年7月，他担任Refrigeration Supplies Distributor公司（制冷和加热控制的分销批发商和制造商）的总会计师。从1995年3月到1997年4月，他担任Refrigeration Supplies Distributor公司的总会计师助理。他曾担任McGladrey & Pullen公司的注册会计师，并持有南加利福尼亚大学（the University of Southern California）的工商管理硕士学位，以及加州大学尔湾分校（the University of California， Irvine）的经济学学士学位。
Paul A. Holtwas appointed Chief Financial Officer in April 2015. Prior to joining NantHealth, Mr. Holt served as Chief Financial Officer of Quality Systems, Inc. NASDAQ: QSII, a healthcare information technology and services company, from 2000 to April 2015. He was Controller of Quality Systems from January 2000 to May 2000. Mr. Holt was the Controller of Sierra Alloys Co., Inc., a titanium metal manufacturing company, from August 1999 to December 1999. From 1995 to 1999 he was Controller of Refrigeration Supplies Distributor, the largest independently owned wholesale distributor and manufacturer of refrigeration supplies and heating controls in the western United States. From 1990 to 1995 Mr. Holt was a Certified Public Accountant at McGladrey & Pullen, LLP. Mr. Holt holds an MBA from the University of Southern California and a BA in Economics (cum laude) from the University of California, Irvine.- Paul A. Holt， 他于2000年11月被任命为我们的首席财务官。他曾担任我们的总会计师（从2000年1月到2000年5月），并于2000年5月被任命为临时首席财务官。加入我们之前，他曾担任Sierra Alloys公司（钛金属制造公司）的总会计师（从1999年8月到1999年12月）。从1997年5月到1997年7月，他担任Refrigeration Supplies Distributor公司（制冷和加热控制的分销批发商和制造商）的总会计师。从1995年3月到1997年4月，他担任Refrigeration Supplies Distributor公司的总会计师助理。他曾担任McGladrey & Pullen公司的注册会计师，并持有南加利福尼亚大学（the University of Southern California）的工商管理硕士学位，以及加州大学尔湾分校（the University of California， Irvine）的经济学学士学位。
- Paul A. Holtwas appointed Chief Financial Officer in April 2015. Prior to joining NantHealth, Mr. Holt served as Chief Financial Officer of Quality Systems, Inc. NASDAQ: QSII, a healthcare information technology and services company, from 2000 to April 2015. He was Controller of Quality Systems from January 2000 to May 2000. Mr. Holt was the Controller of Sierra Alloys Co., Inc., a titanium metal manufacturing company, from August 1999 to December 1999. From 1995 to 1999 he was Controller of Refrigeration Supplies Distributor, the largest independently owned wholesale distributor and manufacturer of refrigeration supplies and heating controls in the western United States. From 1990 to 1995 Mr. Holt was a Certified Public Accountant at McGladrey & Pullen, LLP. Mr. Holt holds an MBA from the University of Southern California and a BA in Economics (cum laude) from the University of California, Irvine.
- Patrick Soon Shiong
Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.- Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
- Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.